Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

McKesson : 2021 Annual Report

06/08/2021 | 04:35pm EDT

The moments that mattered

Annual Report | Fiscal Year Ended March 31, 2021

One package, one patient, one moment at a time- we delivered

Distribution Scale

Delivered 1/3 of all prescription medicines in North America

Delivered medical-surgical supplies and services to 275,000+ customers

>10,500 owned and banner pharmacies across Canada and Europe

Superior Specialty Assets

US Oncology Research has played a role in

100+ FDAapproved cancer therapies

McKesson supported over 14,000 specialty physicians through distribution and GPO services

#1 distributor in community oncology and key specialties

Biopharma Services

More than 500 biopharma brands served

Increased value to biopharma and enabled >$5B in prescription savings

Supported over 94% of therapeutic areas

Technology Differentiation

19B+ annual pharmacy transactions processed through RelayHealth

Connected to payers representing

94% of U.S. prescription volume

Network of 750,000+ providers and over 50,000 pharmacies

To our valued shareholders:

Looking back on a year like no other in our history, it's not the hours or days that we'll remember, but the moments that mattered-the theme of our Fiscal Year 2021 (FY21) Annual Report. We came together as one team to deliver against our business and financial commitments, embrace new ways of working to support

each other, our customers and the healthcare industry, advance our strategies and invest in our future. FY21 proved that we can work toward our long-term goals while addressing short-termneeds-even in moments of crisis.

Last year, I wrote my annual letter to you at the very onset of COVID-19. Since then, McKesson has played a front and center role to help end the pandemic-working in partnership with our customers and interacting with regulatory authorities and other leading companies to bring personal protective equipment, medications and essential supplies to healthcare facilities and first responders; leveraging our lab capabilities to ramp up the distribution of COVID-19 tests as they came to market; and most recently, having the honor of serving as the centralized distributor of COVID-19 vaccines and the ancillary kits needed to administer them. Through April, we've successfully distributed over 150 million Moderna and Johnson & Johnson COVID-19 vaccines and have assembled enough kits to support the administration of more than 550 million doses of all vaccine types. Even now, we continue to advance our global efforts as we help to vaccinate

the public through our Health Mart pharmacies in the U.S. and many of our international retail pharmacies across Canada and Europe. And we stand ready to support our governments with longer-term recovery efforts.

Our employees continue to be the engine of our success. Despite many demands competing for their attention, our employees continued to show up every day and represent the very best of our values and behaviors. Due to their unwavering commitment and engagement, we were able to navigate through an unprecedented time

in healthcare while advancing our enterprise strategies and making great strides to enhance our culture, further our commitment to diversity and inclusion across our organization and become the best place to work in healthcare. This relentless focus will continue to drive our performance in the year ahead as we respond quickly to the changing demands of our customers and all those who depend on us and advocate for important social changes that will benefit our company, our communities and our global society.


billion in revenue


improvement on adjusted earnings


total shareholder return

FY21 Performance


We delivered consolidated operating profit and adjusted earnings per diluted share growth, including growth across nearly all our businesses. We generated revenues of $238B and adjusted earnings per diluted share was up 15% compared to the prior year. This strong performance allowed us to deliver meaningful results for investors, with a total shareholder return of 48%. We also returned $1B in cash to shareholders as we continue to work to improve our five-year shareholder return performance.

Our U.S. Pharmaceutical segment grew revenues 4% to $189.3B and adjusted operating profit (AOP) grew for the second consecutive year, improving 3% versus the prior year. Our priority in this segment is to deliver the world's highest-qualitysupply chain to our customers and manufacturing partners, leveraging differentiated assets in the areas of specialty and oncology.

Our focus on cost and working capital efficiencies underpins this progress and helps fuel investments for growth across the company.

Prescription Technology Solutions grew revenues despite market prescription volume levels lower than pre-COVID-19levels throughout the entire fiscal year. Revenues were $2.9B, up 7%, and AOP was flat to FY20. We're continuing to invest in innovation in this segment, and despite this year's challenges, we've been very successful in adding new brands to our platforms.

Last year, I shared with you that we had launched Access for More Patients (AMP), which helps patients with real-time benefit checks and electronic prior authorizations. Not only was this new product profitable in FY21, but, more importantly, it helps patients by reducing the wait time between when

a medication is first prescribed and when patients start therapy by up to 50%. AMP is a core example of our investment in innovation that is now contributing to profit growth.

Medical-Surgical Solutions grew revenues 22% to $10.1B, and AOP 19%. In FY21, Medical-SurgicalSolutions played a central role in providing supplies to our primary and extended care customers at a critical time of need. Demand within this segment was volatile throughout the fiscal year

for products such as PPE and COVID-19 tests, and our procurement teams worked diligently to find the supplies our customers needed to treat their patients at a time when demand was high and pricing was volatile. Despite fewer patient medical visits and elective procedures in FY21, I'm proud of the way the business responded to the needs of our customers, and I am confident that as patients return to consume healthcare and see their community-based providers, our core business is positioned well for growth heading into Fiscal Year 2022 (FY22).

Our International segment revenues were $36.0B, down 6% on a reported basis. The year-over-year decline was driven by the contribution of McKesson's German wholesale business to a joint venture with Walgreens Boots Alliance. AOP increased 5% on a reported basis, driven by solid execution, efficiencies through utilization of shared services, and continued expense controls and management despite lower foot traffic in many of our retail pharmacies across Europe and Canada, where the pandemic still lags the recovery we're seeing in the U.S. Over the past several years, we've taken deliberate actions to address our cost structure and evolve our retail footprint in these markets, and we saw benefits from those actions this fiscal year. We are also very disciplined in how we operate these businesses, as evidenced by our thoughtful exit of unprofitable customers at the onset of the fiscal year in our Canadian business.

Executing our McKesson Strategy

Two years ago, we introduced a refreshed McKesson strategy. Since this time, we have made great progress in advancing our growth strategy as defined by our execution against our five priorities that guide our decision making and investments across the enterprise.

1Building an integrated Oncology Services business

We continue to focus on delivering innovative solutions in areas like oncology where there is critical need and we have deep expertise. In FY21, we made great progress on this front, launching Ontada, our new insights-driven oncology company. Still in its infancy, Ontada has already reached some impressive milestones, including the formation of a strategic alliance with Amgen to improve cancer care in the community oncology setting, and establishing MYLUNG, a large-scale,real-world research study (with The US Oncology Network and other scientific institutions) to improve treatment for non-small cell lung cancer. In addition, we were pleased to add more practices and over 100 providers to The US Oncology Network in FY21. Today, through The US Oncology Network and our nonaffiliated provider business, we're connected to over 14,000 specialty physicians. And our oncology technology platform has supported millions of patient journeys, providing us access

to real-world outcomes, data and research.

2Expanding our Biopharma Services

Similarly, we also continue to expand the services and support we provide to the biopharma industry to improve access, affordability and, ultimately, drive better outcomes for patients. In FY21, we brought together our RelayHealth Pharmacy, CoverMyMeds and RxCrossroads businesses as Prescription Technology Solutions. Together, these businesses are focused on innovating and automating the ways in which biopharma connects with patients, pharmacies and providers. In FY21, our access solutions helped over 50 million patients start therapies after their original prescription was

denied coverage, and our affordability solutions helped patients save over $5B in out-of-pocket prescription costs. Ultimately, our solutions help patients begin therapies faster and stay on those therapies longer. This value is reflected by the over 500 biopharma brands we support today, covering nearly every therapeutic area.

3Strengthening our core business

We continue to strengthen our core businesses to enable strong cash flow generation for innovation and future investments. At McKesson, this means driving operational excellence and efficiency while making selective investments. This allows us to continue providing the highest level of service and support to our customers while funding our long-term growth strategy.

In FY21, we invested in our core across the entire organization including investments in our U.S. Pharmaceutical segment and our International segment. For example, through a partnership with Vanderbilt Health Rx Solutions, we expanded our integrated pharmacy services for specialty clinics to help them address unique challenges and develop sustainable programs. In Canada, in alignment with investments to expand capacity in our distribution network and create the Supply Chain of the Future, we signed a Letter of Agreement with Walmart to be their distribution partner across the country. And in Europe, online sales nearly doubled after enhancing our e-commerce offerings to support a more digital and consumer-centric healthcare experience.


McKesson Corporation published this content on 08 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2021 20:34:04 UTC.

© Publicnow 2021
07/30MCKESSON : REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic..
07/27W. Va. city, drug distributors trade final words in landmark opioid trial
07/26INSIDER TRENDS : McKesson Insider Receives Stock Award, Buy Trend Intact
07/26INSIDER TRENDS : McKesson Insider Receives Stock Award, Trend of Buys Extended
07/26MCKESSON : Submission of Matters to a Vote of Security Holders (Form 8-K)
07/26MCKESSON CORP : Submission of Matters to a Vote of Security Holders, Financial S..
07/26Declaration of Voting Results by McKesson Corporation
07/26MCKESSON : Hikes Quarterly Dividend by 12% to $0.47 a Share, Payable Oct. 1 to S..
07/26MCKESSON : Raises Quarterly Dividend by 12% to $0.47 Per Share
07/26McKesson Corporation Raises Quarterly Dividend, Payable on October 1, 2021
More news
Financials (USD)
Sales 2022 249 B - -
Net income 2022 2 720 M - -
Net Debt 2022 748 M - -
P/E ratio 2022 11,8x
Yield 2022 0,86%
Capitalization 31 526 M 31 526 M -
EV / Sales 2022 0,13x
EV / Sales 2023 0,12x
Nbr of Employees 67 500
Free-Float 57,3%
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 203,83 $
Average target price 222,38 $
Spread / Average Target 9,10%
EPS Revisions
Managers and Directors
Brian Scott Tyler Chief Executive Officer & Director
Britt J. Vitalone Chief Financial Officer & Executive Vice President
Edward A. Mueller Independent Chairman
Nancy Flores Chief Technology & Information Officer, EVP
Donald R. Knauss Independent Director
Sector and Competitors